Education
About Us
Working with TipRanks
Follow Us
Diaceutics (GB:DXRX)
LSE:DXRX
Total Valuation
Diaceutics has a market cap or net worth of $100.11M. The enterprise value is 92.48M.
Market Cap$100.11M
Enterprise Value92.48M
Share Statistics
Diaceutics has 84,798,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,798,380
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Diaceutics’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -4.62%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-4.62%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee128.80K
Profits Per Employee-9.49K
Employee Count184
Asset Turnover0.51
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Diaceutics is -41.97. Diaceutics’s PEG ratio is 0.12.
PE Ratio-41.97
PS Ratio4.06
PB Ratio1.80
Price to Fair Value1.80
Price to FCF-20.68
Price to Operating Cash Flow55.89
PEG Ratio0.12
Income Statement
In the last 12 months, Diaceutics had revenue of 23.70M and earned -1.75M in profits. Earnings per share was -0.02.
Revenue23.70M
Gross Profit19.71M
Operating Income-2.72M
Pretax Income-2.44M
Net Income-1.75M
EBITDA2.36M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 2.11M and capital expenditures -125.00K, giving a free cash flow of 1.99M billion.
Operating Cash Flow2.11M
Free Cash Flow1.99M
Free Cash Flow per Share0.02
Dividends & Yields
Diaceutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change15.05%
50-Day Moving Average128.87
200-Day Moving Average129.04
Relative Strength Index (RSI)45.34
Average Volume (3m)62.03K
Important Dates
Diaceutics upcoming earnings date is Sep 15, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateSep 15, 2025
Ex-Dividend Date―
Financial Position
Diaceutics as a current ratio of 6.40, with Debt / Equity ratio of 0.39%
Current Ratio6.40
Quick Ratio6.40
Debt to Market Cap0.00
Net Debt to EBITDA-6.55
Interest Coverage Ratio-41.18
Taxes
In the past 12 months, Diaceutics has paid -692.00K in taxes.
Income Tax-692.00K
Effective Tax Rate0.28
Enterprise Valuation
Diaceutics EV to EBITDA ratio is 24.51, with an EV/FCF ratio of -16.31.
EV to Sales2.44
EV to EBITDA24.51
EV to Free Cash Flow-16.31
EV to Operating Cash Flow44.10
Balance Sheet
Diaceutics has $16.75M in cash and marketable securities with £3.75M in debt, giving a net cash position of -$16.60M billion.
Cash & Marketable Securities$16.75M
Total Debt£3.75M
Net Cash-$16.60M
Net Cash Per Share-$0.20
Tangible Book Value Per Share$0.30
Margins
Gross margin is 75.18%, with operating margin of -11.47%, and net profit margin of -7.37%.
Gross Margin75.18%
Operating Margin-11.47%
Pretax Margin-10.29%
Net Profit Margin-7.37%
EBITDA Margin9.95%
EBIT Margin-10.01%
Analyst Forecast
The average price target for Diaceutics is $210.07, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$210.07
Price Target Upside77.28% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―